Yahoo Finance

Yumanity Therapeutics’ YTX-7739 Demonstrates Prevention of Motor Function Deficits in a Parkinson’s Disease Mouse Model

BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ...
Yahoo Finance

Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers

BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ...
Business Wire

Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Yumanity Therapeutics, a company focused on protecting the vitality of the mind by discovering and developing transformative brain-penetrating small molecule drugs ...
Nasdaq

Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model

Study presented at SNO/NCI Joint Symposium: Targeting CNS Tumor Metabolism About YTX-7739YTX-7739 is Yumanity Therapeutics’ proprietary lead small molecule investigational therapy designed to ...
FierceBiotech

Yumanity's end: J&J pays $26M for neuroscience assets as reverse merger erases biotech

Yumanity Therapeutics has struck two agreements to erase itself from existence. Johnson & Johnson has stepped in to take on Yumanity’s lead program and unpartnered discovery-stage candidates, while ...
Nasdaq

Yumanity Therapeutics’ YTX-7739 Demonstrates Prevention of Motor Function Deficits in a Parkinson’s Disease Mouse Model

The results indicate that YTX-7739 actively engages with its intended target, SCD, in the mouse brain. The observed improvements in pathology and neuron survival, and the resultant correction of motor ...